Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease
Parkinson's disease (PD) is a chronic debilitating disease affecting approximately 1% of the population over the age of 60. The severity of PD is correlated to the degree of dopaminergic neuronal loss. Apomorphine has a similar chemical structure as the neurotransmitter dopamine and has been us...
Saved in:
Main Authors: | Nrupa Borkar (Author), Huiling Mu (Author), René Holm (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2018-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease
by: Felix Agbo, et al.
Published: (2021) -
Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients
by: Eva Thijssen, et al.
Published: (2024) -
Investigation of apomorphine during sleep in Parkinson's: Improvement in UPDRS Scores
by: Miguel A. Pieroni
Published: (2019) -
Apomorphine Targets the Pleiotropic Bacterial Regulator Hfq
by: Florian Turbant, et al.
Published: (2021) -
Apomorphine Suppresses the Progression of Steatohepatitis by Inhibiting Ferroptosis
by: Hiroshi Maeda, et al.
Published: (2024)